Connect With a Global Community of Obesity Drug Development Leaders
The Obesity Drug Development Summit Europe 2025 is the premier platform for pharmaceutical innovators, biotech disruptors, and academic pioneers to collaborate on the next generation of metabolic therapies. With GLP-1s reshaping the landscape, the industry faces critical challenges. These challenges range from lean mass preservation and manufacturing scalability to payer-driven endpoints and patient adherence. Partnering with us positions your brand at the heart of these discussions, offering unparalleled visibility and engagement with 60+ decision-makers driving the future of obesity care.

What to Expect?
Raise Your Brand Awareness
Align your company with the most influential minds in obesity drug development. With targeted branding opportunities, from keynote sponsorships to interactive workshops. You’ll showcase your innovations to pharma leaders (Novo Nordisk, Eli Lilly, Boehringer Ingelheim), biotech CEOs, and academic KOLs. Features like logo placement, dedicated exhibition space, and digital promotions ensure your solutions are front and centre.
Generate Commercial Opportunities
Forge high-impact partnerships with potential clients, investors, and collaborators. The summit’s curated roundtables and networking breaks are designed to connect you with stakeholders actively seeking solutions in drug delivery tech such as oral peptides and sustained-release injectables, precision medicine such as biomarkers and phenotyping tools, and manufacturing innovations.
Uncover the Next Market Trend
Gain early insights into emerging therapies and regulatory shifts shaping the obesity space. Partner-led workshops and closed-door discussions reveal unmet needs in combination therapies, reimbursement strategies, and patient-centric endpoints, helping you stay ahead of the curve.
Powering Innovation in Obesity Drug Development
Our attendees from 60+ leading biopharma, biotech, and academic institutions, are actively seeking service and solution providers with specialized capabilities to overcome critical challenges in obesity drug development. Whether you specialise in precision trial design, novel drug delivery, or manufacturing scalability, partnering with us connects you directly with decision-makers shaping the future of metabolic therapies.
Precision Biomarkers & Patient Stratification
Why it matters:
With obesity now recognized as a heterogeneous disease, pharma needs advanced phenotyping tools, and real-world data analytics to identify high-response patient subsets and optimize trial design. Your opportunity to showcase diagnostics, digital health platforms, or RWE solutions that enable targeted therapies and payer-friendly endpoints.
Next-Gen Drug Delivery & Formulation
Why it matters:
The shift toward oral GLP-1s, sustained-release injectables, and cost-effective peptide production demands innovations in formulation tech, cold chain alternatives, and bioavailability enhancement. Highlight nanoparticle delivery, oral peptide tech, or extended-release platforms to partners struggling with adherence and scalability.
Manufacturing & Scalability Solutions
Why it matters:
Peptide production bottlenecks, supply chain gaps, and sustainability pressures are delaying access to life-changing therapies. Promote continuous manufacturing, green chemistry, or modular production systems to developers racing to meet global demand.
Audience Composition
Company Type

Attendee Seniority

Attending Companies Include









Get in Touch
Take advantage of our bespoke sponsorship opportunities to achieve your commercial goals. Email us if you would like to get involved and discuss a bespoke package suited to your needs.

Molly Biggin
Partnerships Director
Obesity Drug Development Summit Europe